Published in Acta Pharmacol Sin on May 02, 2016
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos (2010) 3.06
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol (2008) 2.26
CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke (2013) 2.12
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol (2008) 2.10
Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol (2005) 1.98
Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation (2003) 1.91
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol (2007) 1.89
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol (2006) 1.84
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J (2011) 1.71
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66
An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents. J Virol Methods (1991) 1.65
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost (2006) 1.53
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv (2013) 1.50
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos (2007) 1.40
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol (2005) 1.25
Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost (1999) 1.08
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother (2010) 1.03
Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat (2004) 1.03
Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics (2006) 0.97
Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci (2012) 0.96
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol (2013) 0.95
Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis (2007) 0.93
The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment Pharmacol Ther (2009) 0.92
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet (2009) 0.92
Single nucleotide polymorphisms of the pregnane x receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology (2008) 0.87
Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet (2015) 0.86
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol (2012) 0.84
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta (2007) 0.83
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting. Blood Coagul Fibrinolysis (2013) 0.83
Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol (2013) 0.82
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One (2014) 0.82
Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences. Cardiovasc Ther (2013) 0.82
Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study. Eur J Pharmacol (2014) 0.81
Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol (2009) 0.81
Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Pharmacology (2013) 0.78
The clopidogrel-statin interaction. Circ J (2014) 0.76
Genetic variations of NR2A1 in Asian populations: implications in pharmacogenetics studies. Drug Metab Pharmacokinet (2012) 0.76
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. Exp Ther Med (2014) 0.76
Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. Acta Pharmacol Sin (2015) 0.78
Roles of P-glycoprotein and multidrug resistance protein in transporting para-aminosalicylic acid and its N-acetylated metabolite in mice brain. Acta Pharmacol Sin (2014) 0.77
Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol Sin (2015) 0.76
Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol Sin (2016) 0.75